Evidence map›Paper›PMID 20516682›Full record

GuidelineCerebrovascular diseases (Basel, Switzerland)2010

Stroke: working toward a prioritized world agenda.

Vladimir Hachinski, Geoffrey A Donnan, Philip B Gorelick, Werner Hacke, Steven C Cramer, Markku Kaste, Marc Fisher, Michael Brainin, Alastair M Buchan, Eng H Lo and 44 more

Open access · bronzeAbstract readConsensus StatementGuideline
In one paragraph

Guideline in Cerebrovascular diseases (Basel, Switzerland), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Rehabilitation--emerging technologies, innovative therapies, and future objectives.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2011
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

54 authors at 20 institutions in 17 countries.

Vladimir HachinskiDepartment of Clinical Neurological Sciences, London Health Sciences Center, University of Western Ontario, and St. Joseph's Healthcare London, Ontario, Canada.
Geoffrey A Donnan
Philip B Gorelick
Werner Hacke
Steven C Cramer
Markku Kaste
Marc Fisher
Michael Brainin
Alastair M Buchan
Eng H Lo
Brett E Skolnick
Karen L Furie
Graeme J Hankey
Miia Kivipelto
John Morris
Peter M Rothwell
Ralph L Sacco
Sidney C Smith
Yulun Wang
Alan Bryer
Gary A Ford
Costantino Iadecola
Sheila C O Martins
Jeff Saver
Veronika Skvortsova
Mark Bayley
Martin M Bednar
Pamela Duncan
Lori Enney
Seth Finklestein
Theresa A Jones
Lalit Kalra
Jeff Kleim
Ralph Nitkin
Robert Teasell
Cornelius Weiller
Bhupat Desai
Mark P Goldberg
Wolf-Dieter Heiss
Osmo Saarelma
Lee H Schwamm
Yukito Shinohara
Bhargava Trivedi
Nils Wahlgren
Lawrence K Wong
Antoine Hakim
Bo Norrving
Stephen Prudhomme
Natan M Bornstein
Stephen M Davis
Larry B Goldstein
Didier Leys
Jaakko Tuomilehto
Stroke Synergium
Center for American Progress · USAllen Institute for Brain Science · USScience Approach (United States) · USInternational Drug Development · FRWorld Wide Web Consortium · USCARE Canada · CAAmerican Heart Association · USCornell University · USDuke University · USDurham VA Medical Center · USFlorey Institute of Neuroscience and Mental Health · AUGlaxoSmithKline (United States) · USGroote Schuur Hospital · ZAHeidelberg University · DEJohn Radcliffe Hospital · GBKarolinska Institutet · SEKing's College London · GBLondon Health Sciences Centre · CAMassachusetts General Hospital · USMax Planck Institute for Metabolism Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe aim of the Synergium was to devise and prioritize new ways of accelerating progress in reducing the risks, effects, and consequences of stroke.

methodsPreliminary work was performed by 7 working groups of stroke leaders followed by a synergium (a forum for working synergistically together) with approximately 100 additional participants. The resulting draft document had further input from contributors outside the synergium.

resultsRecommendations of the Synergium are: Basic Science, Drug Development and Technology: There is a need to develop: (1) New systems of working together to break down the prevalent 'silo' mentality; (2) New models of vertically integrated basic, clinical, and epidemiological disciplines; and (3) Efficient methods of identifying other relevant areas of science. Stroke Prevention: (1) Establish a global chronic disease prevention initiative with stroke as a major focus. (2) Recognize not only abrupt clinical stroke, but subtle subclinical stroke, the commonest type of cerebrovascular disease, leading to impairments of executive function. (3) Develop, implement and evaluate a population approach for stroke prevention. (4) Develop public health communication strategies using traditional and novel (e.g., social media/marketing) techniques. Acute Stroke Management: Continue the establishment of stroke centers, stroke units, regional systems of emergency stroke care and telestroke networks. Brain Recovery and Rehabilitation: (1) Translate best neuroscience, including animal and human studies, into poststroke recovery research and clinical care. (2) Standardize poststroke rehabilitation based on best evidence. (3) Develop consensus on, then implementation of, standardized clinical and surrogate assessments. (4) Carry out rigorous clinical research to advance stroke recovery. Into the 21st Century: Web, Technology and Communications: (1) Work toward global unrestricted access to stroke-related information. (2) Build centralized electronic archives and registries. Foster Cooperation Among Stakeholders (large stroke organizations, nongovernmental organizations, governments, patient organizations and industry) to enhance stroke care. Educate and energize professionals, patients, the public and policy makers by using a 'Brain Health' concept that enables promotion of preventive measures.

conclusionsTo accelerate progress in stroke, we must reach beyond the current status scientifically, conceptually, and pragmatically. Advances can be made not only by doing, but ceasing to do. Significant savings in time, money, and effort could result from discontinuing practices driven by unsubstantiated opinion, unproven approaches, and financial gain. Systematic integration of knowledge into programs coupled with careful evaluation can speed the pace of progress.

Indexed as

Global HealthStrokeBiomedical ResearchCooperative BehaviorEvidence-Based MedicineHealth PolicyHealth PrioritiesHealth Services ResearchHumansInternational CooperationNational Health ProgramsOrganizational ObjectivesPrognosis

Identifiers

PMID20516682
PMCPMC3221270
OpenAlexW1970926060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.